title: Molecular Heterogeneity of Triple Negative Breast Cancer.
abstract: Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.
authors.affiliation: Department of Medicine; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, TN.
authors.forename: Vandana G
authors.initials: VG
authors.lastname: Abramson
authors.affiliation: Department of Medicine; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, TN.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
keywords: TNBC; Triple negative breast cancer; gene expression profiles; targeted therapy